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Evaluation of AggreGuide A- 100 for monitoring of antiplatelet 
therapy
Dual antiplatelet therapy with acetylsalicylic acid (ASA) and a thien-
opyridine platelet P2Y12 ADP receptor antagonist is widely pre-
scribed as secondary prevention in acute coronary syndrome and 
following percutaneous coronary intervention. Clopidogrel is the 
most frequently prescribed P2Y12 antagonist, though variability in 
its pharmacokinetic and pharmacodynamic effect is extensively de-
scribed. It is an orally administered prodrug that needs metaboliza-
tion in the liver in order to exert its antiplatelet effect. Differences 
in the rapidity and extent of this effect are partially due to genetic 
variations in the CYP2C19 enzyme that metabolizes the pro- drug 
clopidogrel in its active metabolite.1,2 Other factors that may con-
tribute to the variable anti- platelet effect of clopidogrel are differ-
ences in absorption (diet, polymorphisms in the ABCB1 transporter 
molecule), smoking, drug interactions, inherent variations in platelet 
function before clopidogrel administration and other patient- related 
factors (obesity, diabetes mellitus, renal dysfunction, inflammation, 
age…).3 Similarly, an unpredictable response of platelets to ASA has 
been reported and has been related to poor clinical outcome, al-
though described prevalence of aspirin resistance varies from <1% 
to 57% according to different publications.4-6
A recent review of Michelson et al3 focused on the clinical ben-
efit for monitoring of antiplatelet therapy and found that available 
evidence is not sufficiently strong to support routine use of labora-
tory tests for monitoring platelet function in patients with so- called 
aspirin or clopidogrel resistance. According to the American Heart 
Association/American College of Cardiology 2011 guideline and the 
2014 European Society of Cardiology guideline, testing may be in-
dicated in selected patients at risk for poor clinical outcome after 
percutaneous coronary stenting.7,8 Tailored treatment based on lab-
oratory results may be a solution for the wide inter- laboratory vari-
ability of response to clopidogrel.9
Multiple options exist for monitoring of antiplatelet therapy.9,10 
Light- transmission aggregometry (LTA) is considered the historical 
diagnostic gold standard.10,11 It is an adaptable technique as mul-
tiple agonists can be added in different concentrations. Yet, this 
technique is expensive, laborious, time- consuming, needs high vol-
umes of citrate plasma and suffers from high intra- and inter- patient 
variation. Furthermore, technicians need specialized training, diag-
nostic cut- offs are uncertain and the method is poorly standardized. 
Therefore, this technique is mostly restricted to specialized labora-
tories.10,11 Different point- of- care (POC) analyzers, which use low- 
volume whole blood samples, are available as fast and easy- to- use 
alternatives to LTA. One of these POC platelet aggregometers is the 
AggreGuide A- 100 (Aggredyne, Houston, TX, USA), which uses a 
laser source for measurement of light scattering. The AggreGuide 
A- 100 is designed to be simple and fast, without need for special-
ized training, no blood preparation or centrifugation, small blood 
volume and no reagent handling. A previous study already evaluated 
the effectiveness of this analyzer to detect aspirin- induced platelet 
dysfunction at low and high doses of aspirin.12 It was our aim to eval-
uate the performance of the AggreGuide A- 100 as an alternative less 
labor- intensive method for monitoring responsiveness of platelets to 
dual antiplatelet therapy ASA and clopidogrel.
During a 3- year period (December 2014- December 2017), 72 
citrated whole blood samples (BD Vacutainer, Becton Dickinson, 
Plymouth, UK) from patients on long- term dual antiplatelet therapy 
with ASA (80 mg once daily) and clopidogrel (75 mg once daily) were 
sent to the laboratory and analyzed within 4 hours. Samples were 
obtained from patients with intracranial stents who were consult-
ing the department of vascular and interventional radiology in the 
Ghent University Hospital in Belgium. For these patients, monitor-
ing of antiplatelet therapy was ordered because resistance to anti-
platelet therapy was suspected due to re- occurrence of an ischemic 
event despite the use of ASA and clopidogrel. LTA was performed 
on Chrono- Log 700 (Chrono- Log, Havertown, PA, USA) according 
to the North American Consensus Guideline on platelet function 
testing.13 Platelet- rich citrate plasma was obtained after centrifu-
gation (10 minutes, 180 g/min) (Hettich Universal 32; DJB Labcare, 
Buckinghamshire, UK). LTA curves were assessed after addition 
of 25 μL of the agonists adenosine diphosphate (ADP) (2.5 and 
5 μmol/L), collagen (2.5 and 5 μg/mL), ristocetin (0.5 and 1.5 mg/
mL), epinephrine (10 μmol/L), arachidonic acid (AA) (1 mmol/L), 
and thromboxane A2 analogue (1 μmol/L) to 225- μL platelet rich 
citrate plasma. Light transmission was recorded during 6 minutes 
and compared to platelet poor plasma. Maximal aggregation and 
disaggregation of platelets activated with ADP was evaluated for 
effect of clopidogrel and maximal aggregation and disaggregation 
of epinephrine and AA was assessed for effect of ASA. For mea-
surable effect of therapy, maximal aggregation for these agonists 
should be lower than 50% and/or significant disaggregation, ar-
bitrarily defined as greater than 20%, should be present.10,13 For 
AggreGuide A- 100, Platelet Activity Index (PAI), was measured on 
citrated whole blood after stimulation of platelets with the agonists 
thrombin- receptor activating peptide (TRAP) (functions as an in-
ternal control), ADP (estimate for response to clopidogrel) and AA 
(estimate for response to ASA). To each disposable test cartridge, 
which contained a freeze- dried agonist, 164 μL of whole blood was 
added. Other agonists could not be assessed since only AA, ADP, 
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and TRAP cartridges are commercially available. Similar to LTA, the 
platelet aggregation is measured by the difference in light scattering. 
For measureable effect of antiplatelet therapy, PAI for ADP and AA 
should be lower than the reference values, as indicated by the manu-
facturer, for these agonists (4- 9 for ADP and 3- 9 for AA). Sensitivity 
of AggreGuide A- 100 compared to LTA was assessed and weighted 
kappa correlation coefficient was calculated using Medcalc® statis-
tical software (Mariakerke, Belgium).
Additionally, check of reference values was performed ac-
cording to the CLSI C23- A3 protocol by analysis of 23 healthy 
volunteers.14
Lot- to- lot variability for AggreGuide A- 100 cartridges was as-
sessed by analyzing 15 samples with 2 different lots. This study was 
approved by the local ethical committee.
Our results show a poor comparability of AggreGuide A- 100 
to LTA. When manufacturer’s reference values were applied, 33% 
of samples were discordant for both ASA and clopidogrel. 36% of 
samples were discordant for only one agonist (25% discordant for 
clopidogrel, 11% discordant for ASA). Mostly falsely normal results 
were found for AggreGuide A- 100: PAI was within reference range 
for AggreGuide A- 100 while for LTA an effect of antiplatelet ther-
apy on platelet aggregation was clearly measurable. Only 31% of 
samples correlated entirely with LTA. For detection of clopidogrel 
effect, sensitivity of AggreGuide A- 100 was 40% compared to LTA. 
Weighted kappa correlation coefficient was only 0,019 (95% con-
fidence	 interval	 [CI]:	−0.018	to	0.056),	showing	no	association	be-
tween both methods. For ASA, calculated sensitivity was 55% and 
weighted	kappa	correlation	coefficient	was	0,071	 (95%	CI:	−0.082	
to 0.224) (Table 1). Specificity could not be assessed since no normal 
samples were included in the method comparison.
AggreGuide A- 100 only assesses a decrease in aggregation. 
Disaggregation of platelets following maximal aggregation (>50%) 
after stimulation with one of the agonists is however also a sign of 
treatment response, although this is not detected by the AggreGuide 
A- 100. This seems to be particularly a problem for evaluation of 
clopidogrel response. For 24% of samples, only disaggregation after 
ADP stimulation was observed on LTA without a decrease in maxi-
mal aggregation. Consequently, all these samples were falsely nor-
mal with AggreGuide A- 100, contributing to the low sensitivity for 
clopidogrel effect.
The difference in sample matrix in both tests (whole blood 
for AggreGuide A- 100, platelet- rich plasma for LTA) could also 
TABLE  1 2 × 2 table for assessment of effect of clopidogrel (A) 
and acetylsalicylic acid (ASA) (B) therapy. Platelet Activity Index for 
the ADP cartridge (for assessment of clopidogrel; reference values 
4- 9) and the AA cartridge (for assessment of ASA; reference values 





LTA + 29 42 71
− 0 1 1
Total 29 43 72
B
LTA + 35 29 64
− 3 5 8
Total 38 34 72
F IGURE  1 Observed Platelet Activity 
Indices (PAI) of arachidonic acid (AA) 
and ADP cartridges of patients on dual 
antiplatelet therapy acetylsalicylic acid 
and clopidogrel. The bold horizontal 
line indicates the manufacturer’s PAI 
reference interval for AA, the dotted line 
indicates the PAI reference interval for 
ADP
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contribute to the poor correlation observed between both methods. 
Although LTA is still considered the reference method for monitor-
ing of platelet responses,10,13 some publications state that whole 
blood platelet impedance lumiaggregometry (WBA) is more sensi-
tive than LTA for monitoring of antiplatelet therapy. Furthermore, 
since smaller sample volumes are required and specimen processing 
is easier, WBA may be preferred above LTA. On the other hand, in 
WBA, whole blood compound such as Von Willebrand Factor, red 
blood cells, white blood cells, and platelet count may influence the 
test result.10,15 For monitoring clopidogrel therapy, vasodilator- 
stimulated phosphoprotein (VASP) phosphorylation flow cytometric 
assessment has been proposed as a better alternative to LTA since 
the phosphorylation status of VASP is a P2Y12- receptor- specific 
method.16,17
Figure 1 shows the frequency of the observed PAI’s for ADP and 
AA in the different samples. Our findings differ from what was pre-
viously described by Fisher et al10 They found that the AggreGuide 
A- 100 can effectively measure a decrease in platelet aggregation in 
patients taking low or high dose aspirin. However, this study was 
conducted in healthy volunteers taking aspirin instead of real pa-
tient samples. Furthermore, the effect of antiplatelet therapy was 
assessed in a different way. In the publication of Fisher et al, the PAI 
from samples drawn under therapy was compared to baseline PAI 
levels before start of therapy, whereas in our study, the observed 
PAI for samples drawn under therapy was compared to the PAI ref-
erence range. Since there were no baseline values before start of 
treatment for PAI of ADP and AA available in our study, it was not 
possible to monitor this decrease in PAI after treatment initiation. 
Overall, a poor standardization between different platelet function 
tests for monitoring of ASA and clopidogrel is described in the litera-
ture.18-20 This low standardization is one of the reasons why routine 
monitoring of antiplatelet therapy is not recommended.3,9
Check of reference values was successful since <10% of sam-
ples from healthy volunteers fell outside specified reference ranges 
(Figure 2).14 However, we observed that, in our population, the lower 
limit for AA could be increased from 3 to 4 since all healthy volun-
teers had PAI’s for AA higher than 4. When a cut- off of 4 instead of 
3 is applied for AA, comparison with LTA is slightly better: sensitivity 
for detection of ASA therapy increases from 55% to 67%. Analogous, 
percentage of discordant samples decreased from 33% to 24% and 
percentage of samples concordant for both agonists increased from 
25% to 35%.
Lot- to- lot variability was high: for 7/15 samples (47%), inter-
pretation was different with at least one of both agonists. For 2 
samples, interpretation was different for clopidogrel, for 3 samples 
interpretation was different for ASA and for 2 samples, results were 
discordant for both agonists. Compared to the current lot, observed 
PAI’s for ADP and AA for the new lot were not consistently higher 
or lower, but discrepant results occurred in both directions.
We conclude that, in this study of 72 patient samples, the 
AggreGuide A- 100 is insufficiently sensitive for monitoring of 
dual antiplatelet therapy with ASA and clopidogrel and shows 
poor correlation to light transmission aggregometry. Moreover, 
lot- to- lot variability is too high to obtain an acceptable reproducibil-
ity of results.
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F IGURE  2 Box- and- Whisker plots for Platelet Activity Indices 
for ADP cartridge (reference values 4- 9) (A) and arachidonic acid 
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